Cat. #153287
pCMV-iNOS Vector
Cat. #: 153287
Sub-type: pcDNA 3.1
Availability: 3-5 days
Target: Inducible Nitric Oxide Synthase
Bacterial Resistance: Kanamycin
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: Helen McCarthy
Institute: Queen's University Belfast
Tool Details
*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)
- Tool name: pCMV-iNOS Vector
- Alternate name: Nitric Oxide Synthase
- Research fields: Cancer;Metabolism;Neurobiology
- Tool sub type: pcDNA 3.1
- Bacterial resistance: Kanamycin
- Description: pCMV-iNOS Plasmid is a human nitric oxide synthase (iNOS) transgene driven by a constitutively active CMV (cytomegalovirus) promoter. Originally developed as an anti-cancer therapeutic with a view to a gene therapy strategies that address hormone refractory prostate cancer (HRPC). Studies in the literature have demonstrated that this plasmid is capable of delaying tumour growth (Adams et al., 2009). The plasmid serves as a useful tool in cardiovascular studies or any physiology associated with vasodilation.
Handling
- Storage conditions: -80° C
- Shipping conditions: Dry Ice
Target Details
- Target: Inducible Nitric Oxide Synthase
Application Details
- Application notes: Recommended for transformation in DH5 alpha bacterial cells, iNOS gene is 4.4kb
Related Tools
- Related tools: phOC-iNOS Vector
References
- Adams et al. 2009. J Gene Med. 11(2):160-8. PMID: 19062185.
- Nitric oxide synthase gene therapy enhances the toxicity of cisplatin in cancer cells.
- Coulter et al. 2008. Gene Ther. 15(7):495-503. PMID: 18256696.
- The radiation-inducible pE9 promoter driving inducible nitric oxide synthase radiosensitizes hypoxic tumour cells to radiation.
- McCarthy et al. 2007. J Gene Med. 9(6):511-20. PMID: 17471586.
- Human osteocalcin: a strong promoter for nitric oxide synthase gene therapy, with specificity for hormone refractory prostate cancer.
- McCarthy et al. 2007. Gene Ther. 14(3):246-55. PMID: 17006546.
- p21((WAF1))-mediated transcriptional targeting of inducible nitric oxide synthase gene therapy sensitizes tumours to fractionated radiotherapy.
- Worthington et al. 2002. Gene Ther. 9(4):263-9. PMID: 11896465.
- Tumour cell radiosensitization using constitutive (CMV) and radiation inducible (WAF1) promoters to drive the iNOS gene: a novel suicide gene therapy.
